Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Arterial Stiffness as a Predictor of Response to Renal Sympathetic Denervation (EFFECTIVENES)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02772939
Recruitment Status : Recruiting
First Posted : May 16, 2016
Last Update Posted : October 8, 2019
Sponsor:
Information provided by (Responsible Party):
Philipp Lurz, University of Leipzig

Brief Summary:
This trial is designed to establish invasive and non-invasive measures of arterial stiffness as potential predictors of treatment response to renal sympathetic denervation

Condition or disease Intervention/treatment Phase
Therapy Resistant Arterial Hypertension Device: Renal sympathetic denervation (RDN) Not Applicable

Detailed Description:
Regardless of the ongoing debate on the general effect of renal sympathetic denervation in therapy resistant hypertension, all trials published so far face the problem of a certain proportion of nonresponders to treatment. Previous data shows, that to some extent this might be attributable to arterial stiffening. Elevated invasive pulse wave velocity as an established marker for arterial stiffness has been found to be associated with nonresponse to renal denervation treatment in a smaller trial population. This trial attempts to assess the predictive value of different invasive and non-invasive markers for arterial stiffness in an adequately powered population.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of Arterial Stiffness as a Predictor of Response to Renal Sympathetic Denervation
Study Start Date : June 2015
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : June 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Renal Denervation
Renal denervation for therapy resistant arterial hypertension
Device: Renal sympathetic denervation (RDN)
Catheter based renal sympathetic denervation for therapy resistant arterial hypertension




Primary Outcome Measures :
  1. Predictive value of noninvasive and invasive measures of arterial stiffness (Pulse wave velocity and central pulse pressure assessed invasively, with a piezoelectric device and MRI-based) [ Time Frame: 3 Months ]
    AUC of ROCs for noninvasive and invasive measures of arterial stiffness in predicting response to renal denervation


Secondary Outcome Measures :
  1. Change in 24h ambulatory blood pressure [ Time Frame: 3 months, 6 months, 12 months ]
  2. Change in exercise blood pressure [ Time Frame: 3 months ]
  3. Predictive value of MRI-assessed aortic distensibility on Change in daytime ambulatory blood pressure [ Time Frame: 3 months, 6 months, 12 months ]
  4. Predictive value of MRI-assessed aortic distensibility on Change in 24 h ambulatory blood pressure [ Time Frame: 3 months, 6 months, 12 months ]
  5. Predictive value of MRI-assessed total arterial compliance on Change in daytime ambulatory blood pressure [ Time Frame: 3 months, 6 months, 12 months ]
  6. Predictive value of MRI-assessed total arterial compliance on Change in 24 h ambulatory blood pressure [ Time Frame: 3 months, 6 months, 12 months ]
  7. comparison of predictive value of invasive pulse wave velocity, invasive central pulse pressure, noninvasive pulse wave velocity, noninvasive central pulse pressure, aortic distensibility, total arterial compliance for Change in ambulatory blood pressure [ Time Frame: 3 months, 6 months, 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with therapy resistant arterial hypertension (>=3 antihypertensive drugs including at least one diuretic without any dosage change in the preceding 4 weeks) and office BP >160 mmHg systolic or 90 mmHg diastolic

Exclusion Criteria:

  • average systolic daytime BP <135 mmHg in 24h ambulatory blood pressure measurement (ABPM)
  • pregnancy
  • known renal artery stenosis
  • >= 1 renal artery diameter < 4 mm
  • life expectancy <6 months
  • participation in any other clinical trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02772939


Locations
Layout table for location information
Germany
Heart Center of the University Leipzig Recruiting
Leipzig, Germany, 04289
Contact: Philipp Lurz, MD, PhD    +49341865252022    Philipp.Lurz@gmx.de   
Principal Investigator: Philipp Lurz, MD, PhD         
Sponsors and Collaborators
University of Leipzig

Layout table for additonal information
Responsible Party: Philipp Lurz, Philipp Lurz, PhD, MD, University of Leipzig
ClinicalTrials.gov Identifier: NCT02772939     History of Changes
Other Study ID Numbers: Effectiveness0001
First Posted: May 16, 2016    Key Record Dates
Last Update Posted: October 8, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Vascular Diseases
Cardiovascular Diseases